Alpha-1-Proteinase Inhibitor (Human)
Brand names: Prolastin-C · Active ingredient: .Alpha.1-Proteinase Inhibitor Human
In short: PROLASTIN-C is an Alpha1-Proteinase Inhibitor (Human) (Alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of Alpha1-PI (alpha1-antitrypsin deficiency). PROLASTIN-C increases antigenic and functional
What is Alpha-1-Proteinase Inhibitor (Human) used for?
PROLASTIN-C is an Alpha1-Proteinase Inhibitor (Human) (Alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of Alpha1-PI (alpha1-antitrypsin deficiency).
PROLASTIN-C increases antigenic and functional (anti-neutrophil elastase capacity, ANEC) serum levels and antigenic lung epithelial lining fluid levels of Alpha1-PI.
Limitations of Use
The effect of augmentation therapy with any Alpha1-PI, including PROLASTIN-C, on pulmonary exacerbations and on the progression of emphysema in Alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trials.
Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C are not available.
PROLASTIN-C is not indicated as therapy for lung disease in patients in whom severe Alpha1-PI deficiency has not been established.
Alpha-1-Proteinase Inhibitor (Human) dosage
For intravenous use after reconstitution only.
The recommended dose of PROLASTIN-C is 60 mg/kg body weight administered intravenously once weekly.
Dose ranging studies using efficacy endpoints have not been performed with any Alpha1-PI product.
The carton and the label on each vial of PROLASTIN-C show the actual amount of functionally active Alpha1-PI in milligrams (as determined by the capacity to neutralize porcine pancreatic elastase).
Allow unopened PROLASTIN-C and diluent vials to warm up to room temperature before reconstitution.
Remove the plastic flip tops from each vial.
Swab the exposed stopper surfaces with alcohol and allow to dry.
Remove the plastic cover from the short end of the transfer needle. Insert the exposed end of the needle through the center of the stopper in the diluent vial.
Remove the cover at the other end of the transfer needle by twisting it carefully.
Invert the diluent vial and insert the attached needle into the PROLASTIN-C vial at a 45° angle (Figure A below). This will direct the stream of diluent against the wall of the product vial and minimize foaming. The vacuum will draw the diluent into the PROLASTIN-C vial.
Remove the diluent vial and transfer needle.
Immediately after adding the diluent, swirl vigorously for 10-15 seconds to thoroughly break up cake, then swirl continuously until the powder is completely dissolved (Figure B below). Some foaming will occur, but does not affect the quality of the product.
Inspect the reconstituted PROLASTIN-C visually for particulate matter and discoloration prior to pooling. A few small particles may remain after reconstitution. If particles are visible, remove by passage through a sterile filter, such as a 15 micron filter used for administering blood products (not supplied).
Pool reconstituted PROLASTIN-C from several vials into an empty, sterile intravenous solution container using aseptic technique. Use the sterile filter needle provided for this purpose.
Keep reconstituted solution at room temperature for administration within three hours.
Visually inspect parenteral drug products for particulate matter and discoloration prior to administration, whenever solution and container permit.
Infuse PROLASTIN-C separately, without mixing with other agents or diluting solutions.
Infuse PROLASTIN-C intravenously at 0.08 mL/kg/min as determined by patient response and comfort. The recommended dosage of 60 mg/kg takes approximately 15 minutes to infuse.
How to take Alpha-1-Proteinase Inhibitor (Human) — instructions & advice from the label
Inform patients of the signs of hypersensitivity reactions including pruritus; generalized urticaria; flushing; swollen lips, tongue, or uvula; wheezing; tightness of the chest; dyspnea; hypotension; and syncope. Advise patients to discontinue use of the product and contact their physician and/or seek immediate emergency care, depending on the severity of the reaction, if these symptoms occur.
Inform patients that PROLASTIN-C is made from human plasma and may carry a risk of transmitting infectious agents that can cause disease (e.g., viruses, the vCJD agent and, theoretically, the CJD agent). Explain that the risk of PROLASTIN-C transmitting an infectious agent has been reduced by screening plasma donors for prior exposure to certain infectious agents, by testing the donated plasma for certain current virus infections, and by inactivating and/or removing infectious agents during manufacturing. …
Warnings & precautions
Do not take this medicine if: PROLASTIN-C is contraindicated in:
IgA deficient patients with antibodies against IgA, due to the risk of severe hypersensitivity.
Patients with a history of anaphylaxis or other severe systemic reaction to Alpha1-PI.
Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. Early signs and symptoms of hypersensitivity reactions may include pruritus; generalized urticaria; flushing; swollen lips, tongue, or uvula; wheezing; tightness of the chest; dyspnea; hypotension; and syncope. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C infusion and begin appropriate therapy. Have epinephrine and other appropriate therapy available for the treatment of any acute anaphylactic or anaphylactoid reaction.
PROLASTIN-C may contain trace amounts of IgA. Patients with known antibodies to IgA, which can be present in patients with selective or severe IgA deficiency, have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions.
Because PROLASTIN-C is made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens. The risk of transmission of infectious agents has been reduced by screening plasma donors for prior exposure to certain infectious agents, by testing for the presence of certain virus infections, and by including steps in the manufacturing process with the demonstrated capacity to inactivate and/or remove certain infectious agents. Despite these measures, this product may still potentially transmit disease. …
Alpha-1-Proteinase Inhibitor (Human) side effects
The most serious adverse reaction observed during clinical trials with PROLASTIN-C was an abdominal and extremity rash in one subject.
The most common adverse reaction observed at a rate of > 5% in subjects receiving PROLASTIN-C was upper respiratory tract infection.
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in practice.
Two separate clinical trials were conducted with PROLASTIN-C: 1.) a 20 week, open-label, single arm safety study in 38 subjects (single-arm open-label trial), and 2.) a 16 week, randomized, double-blind, crossover pharmacokinetic comparability study vs. PROLASTIN in 24 subjects, followed by an 8 week open-label treatment with PROLASTIN-C (randomized double-blinded comparator trial). Thus, 62 subjects were exposed to PROLASTIN-C in clinical trials.
The most serious adverse reaction observed during clinical trials with PROLASTIN-C was an abdominal and extremity rash in one subject. The rash resolved subsequent to outpatient treatment with antihistamines and steroids. Two instances of a less severe, pruritic abdominal rash were observed upon rechallenge despite continued antihistamine and steroid treatment, which led to withdrawal of the subject from the trial. …
About this medicine
PROLASTIN-C is a sterile, white to beige-colored concentrate of Alpha1-PI in lyophilized powder form for reconstitution for intravenous infusion. Each vial contains approximately 1,000 mg of functionally active Alpha1-PI as determined by capacity to neutralize porcine pancreatic elastase. The specific activity of PROLASTIN-C is ≥ 0.7 mg functional Alpha1-PI per mg of total protein. PROLASTIN-C has a purity of ≥ 90% Alpha1-PI (Alpha1-PI protein/total protein). When reconstituted with 20 mL of Sterile Water for Injection, USP, PROLASTIN-C has a pH of 6.6–7.4, a sodium content of 100–210 mM, a chloride content of 60–180 mM and a sodium phosphate content of 13–25 mM. PROLASTIN-C contains no preservative.
PROLASTIN-C is produced from pooled human plasma through modifications of the PROLASTIN process using purification by polyethylene glycol (PEG) precipitation, anion exchange chromatography, and cation exchange chromatography. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 91edab72-c889-470e-8315-1798b5548dca. Read the full official label on DailyMed.